TRT Revenue Model: Subscription vs. Per-Visit Billing Analysis

The Two Dominant TRT Billing Models

Testosterone replacement therapy practices operate under one of two fundamental revenue architectures: per-visit billing, which charges patients for discrete clinical encounters, or subscription billing, which charges a recurring monthly fee that covers medication, labs, and ongoing clinical oversight regardless of how many touchpoints occur in a given month. A third category, the hybrid model, blends both approaches and is increasingly favored by clinics transitioning away from per-visit structures.

The choice between these models is not purely administrative — it determines how revenue accrues, how patient relationships are structured, and whether the practice's financial position is predictable 30, 60, and 90 days in advance. Per-visit billing ties revenue directly to the patient's willingness to schedule. Subscription billing ties revenue to the patient's active enrollment status. These are fundamentally different bets on patient behavior. For the broader business model context, see the guide to launching a profitable TRT/HRT telehealth practice.

The decision is further complicated by insurance versus cash-pay positioning. Insurance-contracted practices face billing rules that restrict bundled subscription fees for covered services, effectively constraining their options. Cash-pay practices have full flexibility to design subscription tiers, set pricing, bundle ancillary medications and labs, and charge recurring fees without CPT code restrictions. The majority of high-revenue TRT practices operate as cash-pay specifically for this reason.

Per-Visit Model: Economics and Limitations

Revenue per encounter

In a per-visit TRT practice, revenue is generated at the point of service. A new patient evaluation typically bills $200–$400 for the initial consultation, which may include history, physical components, and a testosterone prescription. Follow-up visits, typically every 4–12 weeks depending on protocol and patient response, bill $100–$200 each. Injection administration charges $35–$75 per visit if performed in-office. Lab work is ordered separately and either billed to insurance (if accepted) or charged as a patient-pay lab fee of $80–$180 per panel.

This translates to approximately $200–$290 per patient per month when fully active. However, the critical qualifier is "fully active." Per-visit billing is entirely dependent on the patient choosing to schedule. When patients go through busy periods, feel well and deprioritize follow-ups, or experience sticker shock at an unexpected lab charge, they simply stop booking — and revenue evaporates silently.

Scheduling dependency

The per-visit model creates an inverse relationship between operational burden and revenue predictability: the more patients a practice has, the more scheduling infrastructure it must maintain, yet revenue remains unknown until appointments are actually booked and kept. No-show rates in TRT practices average 12–18%. Each no-show represents lost revenue that cannot be recovered because the appointment slot cannot be resold after a last-minute cancellation.

Beyond no-shows, the scheduling dependency creates a staffing tension. Front-desk and scheduling resources must be sized for peak visit volume, but revenue does not arrive until the visit happens. Cash flow lags the work of scheduling, confirming, reminding, and rooming patients by days to weeks.

Seasonal variation

Per-visit TRT practices exhibit significant seasonal revenue variation. January sees elevated visits as patients restart care in the new year. Summer months (June–August) often see 15–25% lower visit volume as patients travel and deprioritize non-urgent appointments. The holiday corridor (Thanksgiving through New Year's) creates another dip. These predictable seasonal valleys require practices to maintain operating reserves or carry debt through low-revenue months — a problem that does not exist in subscription models where revenue is collected regardless of whether a visit occurs.

Subscription Model: MRR, Bundling, and Lab Inclusion

How subscription pricing works for TRT

A TRT subscription bundles the recurring components of care into a single monthly fee. The base subscription typically covers testosterone medication (cypionate or enanthate compound from a partner compounding pharmacy), twice-yearly lab panels (total testosterone, free testosterone, estradiol, hematocrit, PSA, comprehensive metabolic panel), and provider oversight — async messaging, protocol adjustments, and prescription renewals. The patient is billed automatically each month and receives their medication on a recurring shipment schedule.

Premium subscription tiers add ancillary medications (anastrozole, HCG, enclomiphene, or peptide add-ons), expanded lab panels (SHBG, DHT, thyroid panel, cardiovascular markers), priority turnaround on provider messages, and quarterly video consultations. Tiered pricing creates upsell pathways and increases average revenue per patient over time.

Compound inclusion and lab bundling

The most impactful financial lever in a TRT subscription is bundling compounded testosterone. When the clinic operates as a dispenser or works directly with a compounding pharmacy at negotiated rates, medication cost is $30–$60 per month for a standard testosterone cypionate protocol. At a $299 subscription price, the medication represents 10–20% of revenue, leaving substantial margin for clinical overhead and lab costs.

Lab bundling removes a significant patient objection. In a per-visit model, unexpected lab charges of $80–$180 create friction that drives cancellations. When labs are included in the monthly subscription, patients view them as covered rather than additional — removing a primary churn driver and improving the frequency with which patients comply with monitoring requirements.

Predictable MRR and compounding patient value

The financial superiority of subscription billing emerges most clearly over time. A patient who enters a per-visit practice generates irregular revenue that peaks during the first year (new patient evaluation, frequent follow-ups) and declines as the patient stabilizes and visits less often. A subscription patient generates the same MRR in month one as month 24, and any upsell to a higher tier or additional protocol increases their ARPU without requiring a new visit. For how to structure subscription tiers to maximize patient lifetime value, see the guide to TRT pricing strategy and patient lifetime value.

This compounding patient value effect means that a subscription practice's revenue base grows with patient count and is protected against the attrition that silently erodes per-visit revenue. Active subscription count is the single most reliable leading indicator of practice financial health.

Hybrid Models: Base Subscription + Add-On Visits

Hybrid billing models have emerged as the preferred structure for TRT practices that want subscription revenue predictability while accommodating patients who need in-person care. The hybrid architecture uses a base subscription covering medication, labs, and async clinical oversight, with in-person or video visits available as add-ons billed per occurrence.

Common hybrid configurations include:

• Base subscription ($199–$249/mo) + visit credits: The subscription includes two video consultations per year; additional visits are charged at $75–$125 each. Patients who need more frequent touchpoints pay for additional visits; most do not, keeping their cost at the base rate.
• Tiered membership with visit inclusions: A Silver tier ($249/mo) includes one quarterly video consult; a Gold tier ($349/mo) includes monthly provider access and priority labs. Patients self-select the tier that matches their engagement preferences.
• Base subscription + in-office injection visit billing: Patients on self-injection protocols pay the base subscription; patients who prefer in-office injections pay a per-visit injection fee ($45–$75) on top of the subscription. This hybrid captures the visit revenue from high-engagement patients without requiring all patients to pay for visits they don't use.

Financial Comparison at 100, 250, and 500 Patients

The following table models monthly revenue, annual revenue, and 24-month cumulative revenue for per-visit, subscription, and hybrid billing approaches at three common practice scales. Per-visit figures assume a 72% visit completion rate accounting for no-shows and scheduling attrition. Subscription figures assume 3% monthly churn after an initial ramp period. Hybrid figures use base subscription revenue plus modeled add-on visit revenue.

Metric	Per-Visit (100 pts)	Subscription (100 pts)	Per-Visit (250 pts)	Subscription (250 pts)	Per-Visit (500 pts)	Subscription (500 pts)
Avg. monthly rev/patient	$215	$299	$205	$299	$195	$299
Monthly revenue (MRR equiv.)	$15,480	$29,900	$37,125	$74,750	$70,200	$149,500
Annual revenue (Yr 1)	$185,760	$330,120	$445,500	$799,500	$842,400	$1,587,000
24-month cumulative rev.	$334,368	$618,240	$801,900	$1,498,500	$1,515,960	$2,973,000
Revenue predictability	Low	High	Low	High	Low	High
Scheduling staff burden	High	Low	High	Low	Very High	Low
Revenue at risk (seasonal)	15–25%	<3%	15–25%	<3%	15–25%	<3%
Insurance compatible	Yes	No (cash-pay only)	Yes	No (cash-pay only)	Yes	No (cash-pay only)

The 24-month subscription revenue advantage at the 250-patient scale is approximately $697,000 — nearly double the per-visit cumulative revenue. This gap widens at 500 patients due to operational efficiencies that reduce cost per patient in subscription models: fewer scheduling interactions, automated billing, and lower administrative overhead per patient.

The per-visit figures decrease on a per-patient basis at higher volumes because scheduling capacity constraints force longer appointment gaps, reducing the frequency of billable encounters. Subscription revenue per patient is stable regardless of practice size.

Churn Analysis: 24-Month Retention Curves

How subscription and per-visit attrition differ

The comparison of "churn" between per-visit and subscription models requires careful framing. In subscription billing, churn is explicit: a patient cancels their subscription, triggering an immediate reduction in MRR. In per-visit billing, attrition is implicit: a patient simply stops scheduling, and the practice does not recognize this as churn until the provider flags the lapse or the patient re-presents months later. This hidden attrition is typically not measured as a KPI in per-visit practices, which means the actual patient loss rate is often significantly underestimated.

At 24 months, a subscription practice retains approximately 72% of the original patient cohort as active subscribers. A per-visit practice retains approximately 36% of the original cohort as active scheduling patients. The divergence accelerates after month six — the period when post-stabilization TRT patients in a per-visit model begin to self-triage out of regular follow-ups because they feel well and see no immediate urgency to keep booking appointments. Subscription practices relying on automated lab monitoring — see the guide to testosterone lab tracking software — generate proactive patient touchpoints that counteract this post-stabilization drift.

Primary churn drivers by model

Subscription churn drivers: Cost sensitivity (38% of cancellations), relocation or change in lifestyle (22%), dissatisfaction with provider responsiveness (18%), desire for a different protocol not covered by current tier (12%), and insurance changes prompting a switch to covered care (10%). Many of these are addressable with proactive retention outreach triggered by engagement signals in the patient platform.

Per-visit attrition drivers: No-show and appointment abandonment (35%), financial friction from unexpected charges (28%), inconvenience of scheduling for a condition where they "feel fine" (25%), and provider access delays (12%). Most of these are structural to the per-visit model and cannot be resolved without changing the billing structure.

Churn rate improvement over time

Subscription practices benefit from a natural churn rate decline as the patient base matures. Patients who survive the first 12 months on a TRT subscription have demonstrated commitment to the protocol and are significantly less likely to cancel. Monthly churn in a subscription cohort typically starts at 3–4% in months 1–3, declines to 2–2.5% in months 4–12, and stabilizes at 1.5–2% for patients who have been subscribers for over a year. This declining churn profile means the long-term patient base becomes increasingly stable even without new patient acquisition.

Cash Flow: Smoothing Revenue vs. Peaks and Valleys

Cash flow management is where the subscription versus per-visit distinction becomes most operationally significant. Per-visit billing creates a revenue cycle that lags clinical activity: the visit occurs, the charge is created, and payment arrives 0–30 days later for cash-pay encounters or 30–90 days later for insurance-billed encounters. This lag creates a period where the practice has incurred labor and overhead costs but not yet collected the revenue to cover them.

The cash flow problem in per-visit models compounds during seasonal slow periods. When August visit volume drops 20%, revenue 30 days later drops 20%, but payroll, rent, software subscriptions, and supply costs do not. Practices carrying this model must maintain 60–90 days of operating cash reserves to absorb seasonal troughs without operational disruption.

Subscription billing inverts the cash flow structure entirely. Revenue is collected on the renewal date — typically the first of the month or the anniversary of enrollment — before clinical services are delivered. The practice operates on pre-collected revenue, which eliminates the accounts receivable problem and allows precise operating cost management against a known revenue figure.

This has compounding benefits for financial planning. A subscription practice can commit to staffing levels, technology expenses, and facility costs based on confirmed MRR rather than projected visit volume. When practices grow, they can model the exact revenue impact of adding 10, 25, or 50 patients before those patients enroll. Capital allocation becomes a planning function rather than a reactive response to cash position.

Accounts receivable elimination

Per-visit practices carry ongoing accounts receivable that require active management: invoicing, payment follow-up, collections for unpaid balances, and write-offs for uncollectable claims. A 250-patient per-visit practice typically carries $15,000–$40,000 in outstanding accounts receivable at any point, representing revenue earned but not yet collected. Staff time spent on collections is overhead with no clinical value.

Subscription practices have no meaningful accounts receivable beyond failed payments caught in the dunning process. Revenue is collected automatically, failed payment recovery is automated, and uncollectable amounts are resolved within 7–14 days through cancellation rather than extended collections cycles. The administrative efficiency gain from eliminating AR management pays for a significant portion of the technology infrastructure required to run subscription billing.

Insurance Billing vs. Cash-Pay Considerations

Why insurance-contracted TRT practices cannot use pure subscription billing

Insurance contracts require that covered services be billed through claims using CPT codes, with charges at the contracted rate per covered service. Collecting a separate monthly subscription fee that bundles covered services — such as evaluation and management visits or laboratory testing — alongside insurance billing for those same services constitutes improper double-billing and violates the terms of insurance contracts. This is not a gray area; it is an explicit compliance violation that can result in contract termination and regulatory action.

TRT practices that accept insurance for testosterone evaluation and management, lab interpretation, and injection administration must bill per CPT code per encounter. Common codes include:

• 99213 / 99214: Office or outpatient evaluation and management visits (established patient) for prescription management and follow-up
• 96372: Therapeutic injection administration
• 80053: Comprehensive metabolic panel
• 84403: Total testosterone serum assay
• 84402 / 84270: Free testosterone and SHBG
• 82670: Estradiol assay

Hybrid insurance + membership approaches

Insurance-contracted practices can legally charge a membership or concierge fee for services explicitly not covered by insurance: secure patient messaging beyond routine coordination, 24-hour provider access for non-urgent questions, lifestyle and nutrition counseling, care coordination with external providers, and patient platform access. This membership fee must be for non-covered services only and disclosed to patients as separate from their insurance-covered care.

The practical revenue ceiling for this hybrid in insurance-contracted TRT practices is $50–$150 per month for the membership layer, plus the variable insurance-billed encounter revenue. This is substantially lower than a pure cash-pay subscription at $299–$499 per month, which is a primary reason why high-revenue TRT practices increasingly choose to operate entirely outside insurance networks.

The cash-pay case for TRT

The financial argument for cash-pay TRT is compelling at scale. Insurance-contracted practices face reimbursement rates for follow-up visits that typically range from $85–$135 per encounter after contracting discounts, compared to the $100–$200 a cash-pay practice charges per comparable visit. The subscription premium is even more dramatic: a cash-pay subscription practice collects $299 per patient per month versus $85–$135 per encounter for insurance-billed follow-ups with 6–8 weeks between appointments. Over 12 months, the per-patient revenue difference is $3,588 (subscription cash-pay) versus $680–$1,350 (insurance follow-ups at standard frequency). Labs generate additional revenue in cash-pay and are a cost center or breakeven item in insurance billing.

Payment Processing: Recurring Billing, Failed Payments, and Dunning

Setting up recurring billing for TRT subscriptions

TRT subscription billing requires a payment processor that supports recurring charges with HIPAA-compliant data handling. Stripe is the most common infrastructure layer, but must be configured with a Business Associate Agreement and appropriate data handling to meet HIPAA requirements. Purpose-built medical billing platforms layer Stripe's payment rails under HIPAA-compliant infrastructure that includes encrypted patient financial records, audit logging, and prescription verification on each renewal cycle.

The subscription billing setup must handle: initial enrollment charge (which may include a one-time intake or setup fee), recurring monthly charges on the patient's enrollment anniversary or a standardized billing date, automatic prescription verification before processing each renewal to avoid fulfilling orders without valid Rx, and proration for mid-month enrollments and cancellations.

Key configuration decisions include whether to use per-patient anniversary dates (each patient's billing date is their enrollment date) or a unified billing date (all patients billed on the first of the month). Anniversary billing creates smooth daily revenue inflow but requires more complex reporting. Unified billing creates a predictable monthly revenue event but generates a large single-day charge volume that can trigger fraud flags if not pre-coordinated with the payment processor.

Failed payment rates and recovery

Failed payment rates in medical subscription billing average 6–9% per billing cycle. Causes include expired cards (the most common at 45% of failures), insufficient funds (30%), bank authorization declines (15%), and lost or stolen card replacements (10%). Unrecovered failed payments directly reduce MRR and, if uncorrected, lead to subscription cancellation and patient churn.

Dunning sequences

Dunning is the automated process of retrying failed payments and communicating with patients to resolve billing issues before their subscription is cancelled. An effective TRT dunning sequence operates on the following schedule:

• Day 0 (failure): Automatic retry with the same payment method. Send patient a payment failure notification via email and SMS. Do not pause medication shipment on the first failure.
• Day 3: Second payment retry. Send a patient-facing message requesting card update. Include a direct link to the payment update page.
• Day 7: Third retry with the original card. Send a more urgent notification noting that medication shipment will pause if payment is not resolved.
• Day 10: Pause medication fulfillment. Send final notification with a 48-hour window to resolve before subscription suspension. Offer a one-click card update and payment option.
• Day 12: Suspend subscription. Send suspension confirmation with a reactivation link. Patient data is retained for 90 days for easy reactivation.

This sequence, when automated through a medical billing platform, recovers 60–70% of initially failed payments without manual staff intervention. Manual outreach (a call from the front desk) on day 7 increases recovery rates to 75–85% but adds labor cost that must be weighed against the recovered revenue amount.

Smart retries — retrying on days of the week and times of day when bank authorization rates are statistically higher — improve first-retry recovery rates by 15–20%. Most purpose-built medical billing platforms integrate smart retry logic automatically.

Migrating from Per-Visit to Subscription: A Playbook

Transitioning an active per-visit TRT practice to subscription billing is a high-stakes operational change that, executed correctly, generates substantially higher revenue within 90 days of full migration. Executed poorly, it creates patient confusion, disrupts care continuity, and risks losing active patients during the transition window. The following four-phase playbook reflects successful migrations observed in cash-pay TRT practices.

Setting realistic migration expectations

Not all per-visit patients will migrate to subscription billing, and this is acceptable. Patients who visit twice per year or less are unlikely to find the subscription financially advantageous even at the base tier. These patients may be better served by a fee-for-service structure that the practice can maintain in parallel at a higher per-visit rate for non-subscribers. Attempting to force infrequent visitors into subscriptions creates churn rather than retention.

The migration goal is to capture 65–80% of total prior patient revenue in the new MRR base by the end of phase 4, with ongoing subscription growth from new patient enrollment covering and exceeding the remainder within 60–90 additional days. Practices that have executed this migration report total revenue reaching prior annual levels within six months, then growing past them by month nine as subscription compounding takes effect.

Key Metrics to Track for TRT Subscription Billing

Running a TRT subscription practice requires a different analytical framework than per-visit billing. The following metrics dashboard covers the primary indicators that determine practice financial health and trajectory.

Benchmarks by practice scale

Metric	Early Stage (<100 pts)	Growth Stage (100–300 pts)	Scale Stage (300+ pts)
MRR target	$15,000–$30,000	$30,000–$90,000	$90,000+
ARPU target	$250–$299	$299–$349	$349–$499
Monthly churn target	<4%	<3%	<2%
LTV:CAC ratio	3:1+	4:1+	5:1+
Dunning recovery	55%+	65%+	70%+
NRR target	90%+	95%+	100%+

Reporting cadence

MRR, churn, and dunning recovery should be reviewed weekly by practice leadership. LTV, CAC, and NRR are monthly or quarterly metrics — they require sufficient data windows to be meaningful. ARPU trends should be reviewed monthly with attention to whether new patients are enrolling at higher or lower tiers than the current average, which predicts future MRR trajectory before it appears in total revenue figures.